Quoin Pharmaceuticals, Ltd. reported preliminary financial results for first quarter 2026.
“On May 7, 2026 Quoin Pharmaceuticals Ltd. (the “Company”) announced its first quarter 2026 financial results.”
Quoin Pharmaceuticals, Ltd. — fact timeline
Source-grounded facts extracted from Quoin Pharmaceuticals, Ltd.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Quoin Pharmaceuticals, Ltd. reported financial results for fourth quarter and fiscal year 2025.
“Quoin Pharmaceuticals Ltd. (the "Company") announced its fourth quarter and fiscal year 2025 financial results. A copy of the Company's press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.”
Quoin Pharmaceuticals, Ltd. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“April 29, 2024, Quoin Pharmaceuticals Ltd. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 31 consecutive business days (March 14, 2024 through April 26, 2024), the Company’s American Depositary Shares (“ADSs”) did not maintain a minimum closing bid price of $1.00 (“Minimum Bid Price Requirement”) per ADS as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s ADSs and the ADSs will continue to trade on Th”
Quoin Pharmaceuticals, Ltd. shareholders approved approve the issuance of the maximum number of the Company’s ordinary shares represented by ADSs issuable pursuant to the purchase agreement with Alumni Capital LP at the 2024-04-05 meeting.
“The shareholders approved the Alumni Issuance Proposal. The results of the voting for this proposal were as follows: For Against Abstain Broker Non-Votes 56,626 23,469 2,338 0”
Quoin Pharmaceuticals, Ltd. reported the quarter and year ended December 31, 2023 results: net income Net loss for the quarter ended December 31, 2023 was approximately $2.0 million compared to approximately $2.0 million f.
“Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the quarter and year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.